

Intarcia Pre-Commercial Royalty Financing: the Start of a New Trend or One-Off Deal?

May 1, 2015 | Client Update

Boston-based biotech Intarcia Therapeutics announced this week that it had secured \$225 million in a private synthetic royalty financing. The financing is in the form of limited recourse notes that entitle the holders to 1.5% of future net sales of Intarcia's lead product candidate until the borrowed amounts have been repaid in full or the notes mature. The notes are convertible into Intarcia common stock at a conversion price corresponding to an equity valuation of \$5.5 billion, commencing on U.S. regulatory approval of the lead product candidate and ending on the later of the second anniversary of approval or December 31, 2019. The investors were not disclosed, and only summary terms of the deal were released.

If you have any questions regarding the matters covered in this publication, please reach out to any of the lawyers listed below or your usual Davis Polk contact.

Bruce K. Dallas

+1 650 752 2022
bruce.dallas@davispolk.com

Alan F. Denenberg

+1 650 752 2004
alan.denenberg@davispolk.com

Deanna L. Kirkpatrick

+1 212 450 4135
deanna.kirkpatrick@davispolk.com

Richard D. Truesdell, Jr.

+1 212 450 4674
richard.truesdell@davispolk.com

This communication, which we believe may be of interest to our clients and friends of the firm, is for general information only. It is not a full analysis of the matters presented and should not be relied upon as legal advice. This may be considered attorney advertising in some jurisdictions. Please refer to the firm's privacy notice for further details.

Related materials

[Read the full update](#)